CG42GZZ
Nonimaging Nuclear Medicine Uptake Thyroid Gland to None with None, Iodine 131 (I-131) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | C Nuclear Medicine |
| Body System | G Endocrine System |
| Operation | 4 Nonimaging Nuclear Medicine Uptake |
| Body Part | 2 Thyroid Gland |
| Approach | G Iodine 131 (I-131) |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
Introduction of radioactive materials into the body for measurements of organ function, from the detection of radioactive emissions
Procedure Overview
This family describes the radioactive iodine uptake test, a measurement rather than a picture, most often used to evaluate thyroid function. The patient swallows a small dose of radioactive iodine, and a detection probe held over the neck at set time points, commonly four to six hours and again at twenty-four hours, counts how much of the dose the thyroid has absorbed and converts it into a percentage.
Endocrinologists rely on this number to distinguish Graves' disease and toxic nodular goiter, both of which show high uptake, from thyroiditis or excess thyroid hormone intake from pills, which show low uptake despite similar blood test results. The same measurement is also used to calculate the correct dose of radioactive iodine when planning to treat an overactive thyroid or thyroid cancer, since the dose depends on how avidly the gland concentrates iodine.
Anatomy & Axis Detail
Thyroid Gland
The thyroid gland sits low in the anterior neck, straddling the trachea, and its uptake of circulating iodine drives most hormone synthesis. Radioactive iodine uptake testing exploits this physiology directly: a tracer dose is administered orally or intravenously, and a probe measures the percentage taken up by gland tissue at fixed intervals rather than producing a spatial image. This distinguishes hyperthyroid states such as Graves disease and toxic nodular goiter, which show elevated uptake, from thyroiditis or exogenous hormone use, where uptake is suppressed. Documentation should specify the tracer, the timing of measurements (commonly 6- and 24-hour readings), and that no image was generated, since this nonimaging measurement is coded separately from thyroid scintigraphy performed with a gamma camera.
Radionuclide: Iodine 131 (I-131)
Iodine 131 (I-131) identifies use of this radionuclide, which serves both diagnostic thyroid scanning and, at higher doses, therapeutic ablation of thyroid tissue or metastatic thyroid cancer. Its higher energy and longer half-life compared to Iodine 123 make it suited for therapeutic as well as diagnostic use, distinguishing it from the shorter-lived, purely diagnostic I-123.
Coding & Documentation
Coding requires documentation that the study produced a numeric uptake value from a probe count, not an image from a gamma camera. The report typically lists percentage uptake at each measured time point along with the radioiodine dose administered. The recurring assignment error is failing to code this root operation separately when the uptake test and a thyroid scan were both performed during the same visit, since they are frequently ordered and billed together as a single "uptake and scan" study but represent two distinct procedures. Another mistake is confusing this nuclear medicine test with a routine TSH or thyroid antibody blood test, which involves no radiotracer at all.
Commonly Confused With
This family is easily confused with Planar Nuclear Medicine Imaging of the endocrine system performed in the same visit, since both use radioactive iodine, but the uptake test yields only a count-based percentage while the scan produces an actual image. It is also sometimes mistaken for standard endocrine laboratory testing, which is a chemistry-based blood test performed without any radioactive material or nuclear medicine equipment.